Cellectis (the Company) (Euronext Growth ALCLS - NASDAQ CLLS) Announces Participation in Four Upcoming Investor Conferences in September. Cellectis uses its pioneering gene-editing platform to develop life-saving cell and gene therapies.
💼 Business Developments:
No specific business developments reported in this filing.
🌍 Cellectis (CLLS) - Form 6-K Filing
Filing Date: 2022-09-01
Accepted: 2022-09-01 16:56:28
Event Type: Clinical Trial Update
Event Details:
💼 Business Developments:
No specific business developments reported in this filing.
📞 Contact Information: